You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
JTCC will adapt validated tests developed by GTC for DNA and RNA profiling of all cancers in its patients with solid tumors of blood cancers.
In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.
The company uses a combination of transcriptomic and proteomic data combined with machine-learning analysis to identify immune profiles linked to disease.
A pilot project showed that clinics using the InheRET tool were able to gather more complete family history information from patients, which is important for further cancer risk evaluation.